Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus PORTIA 21.
ENSKYCE vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive